Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.

Farrant M, Easton JD, Adelman EE, Cucchiara BL, Barsan WG, Tillman HJ, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Zhao W, Pauls K, Walsh KB, Martí-Fàbregas J, Bernstein RA, Johnston SC.

JAMA Netw Open. 2019 Sep 4;2(9):e1910769. doi: 10.1001/jamanetworkopen.2019.10769.

PMID:
31490536
2.

Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials.

Pan Y, Elm JJ, Li H, Easton JD, Wang Y, Farrant M, Meng X, Kim AS, Zhao X, Meurer WJ, Liu L, Dietrich D, Wang Y, Johnston SC.

JAMA Neurol. 2019 Aug 19. doi: 10.1001/jamaneurol.2019.2531. [Epub ahead of print]

PMID:
31424481
3.

Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.

Johnston SC, Elm JJ, Easton JD, Farrant M, Barsan WG, Kim AS, Lindblad AS, Palesch YY, Zurita KG, Albers GW, Cucchiara BL, Kleindorfer DO, Lutsep HL, Pearson C, Sethi P, Vora N; POINT and Neurological Emergencies Treatment Trials Network Investigators.

Circulation. 2019 Aug 20;140(8):658-664. doi: 10.1161/CIRCULATIONAHA.119.040713. Epub 2019 Jun 26.

PMID:
31238700
4.

Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial.

Sathe AG, Tillman H, Coles LD, Elm JJ, Silbergleit R, Chamberlain J, Kapur J, Cock HR, Fountain NB, Shinnar S, Lowenstein DH, Conwit RA, Bleck TP, Cloyd JC.

Acad Emerg Med. 2019 Aug;26(8):940-943. doi: 10.1111/acem.13811. Epub 2019 Jul 18. No abstract available.

PMID:
31161706
5.

Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.

Tillman H, Johnston SC, Farrant M, Barsan W, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Easton JD.

JAMA Neurol. 2019 Jul 1;76(7):774-782. doi: 10.1001/jamaneurol.2019.0932.

PMID:
31034032
6.

Levetiracetam no better than phenytoin in children with convulsive status epilepticus.

Silbergleit R, Elm JJ.

Lancet. 2019 May 25;393(10186):2101-2102. doi: 10.1016/S0140-6736(19)30896-7. Epub 2019 Apr 17. No abstract available.

7.

Factors Influencing Oral Intake Improvement and Feeding Tube Dependency in Patients with Poststroke Dysphagia.

Wilmskoetter J, Bonilha L, Martin-Harris B, Elm JJ, Horn J, Bonilha HS.

J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1421-1430. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.031. Epub 2019 Apr 5.

PMID:
30962081
8.

Mapping acute lesion locations to physiological swallow impairments after stroke.

Wilmskoetter J, Bonilha L, Martin-Harris B, Elm JJ, Horn J, Bonilha HS.

Neuroimage Clin. 2019;22:101685. doi: 10.1016/j.nicl.2019.101685. Epub 2019 Jan 22.

9.

Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.

Cohen S, Waks Z, Elm JJ, Gordon MF, Grachev ID, Navon-Perry L, Fine S, Grossman I, Papapetropoulos S, Savola JM.

BMC Med Inform Decis Mak. 2018 Dec 20;18(1):138. doi: 10.1186/s12911-018-0714-7.

10.

Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial.

Kimberly WT, Bevers MB, von Kummer R, Demchuk AM, Romero JM, Elm JJ, Hinson HE, Molyneaux BJ, Simard JM, Sheth KN.

Neurology. 2018 Dec 4;91(23):e2163-e2169. doi: 10.1212/WNL.0000000000006618. Epub 2018 Nov 16.

PMID:
30446594
11.

Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage.

Murphy MP, Kuramatsu JB, Leasure A, Falcone GJ, Kamel H, Sansing LH, Kourkoulis C, Schwab K, Elm JJ, Gurol ME, Tran H, Greenberg SM, Viswanathan A, Anderson CD, Schwab S, Rosand J, Shi FD, Kittner SJ, Testai FD, Woo D, Langefeld CD, James ML, Koch S, Huttner HB, Biffi A, Sheth KN.

Stroke. 2018 Nov;49(11):2652-2658. doi: 10.1161/STROKEAHA.118.021799.

PMID:
30355194
12.

Long-Term Outcomes in Patients Aged ≤70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis.

Sheth KN, Petersen NH, Cheung K, Elm JJ, Hinson HE, Molyneaux BJ, Beslow LA, Sze GK, Simard JM, Kimberly WT.

Stroke. 2018 Jun;49(6):1457-1463. doi: 10.1161/STROKEAHA.117.020365. Epub 2018 May 22.

13.

Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.

Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators.

N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16.

14.

Differences in swallow physiology in patients with left and right hemispheric strokes.

Wilmskoetter J, Martin-Harris B, Pearson WG Jr, Bonilha L, Elm JJ, Horn J, Bonilha HS.

Physiol Behav. 2018 Oct 1;194:144-152. doi: 10.1016/j.physbeh.2018.05.010. Epub 2018 May 11.

PMID:
29758228
15.

Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort.

Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA; NINDS NET-PD Investigators.

J Neurol Sci. 2017 Jun 15;377:137-143. doi: 10.1016/j.jns.2017.04.011. Epub 2017 Apr 11.

16.

Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.

Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS; NINDS NET-PD Investigators.

Parkinsonism Relat Disord. 2016 Dec;33:127-133. doi: 10.1016/j.parkreldis.2016.10.005. Epub 2016 Oct 8.

17.

Communicating with participants during the conduct of multi-center clinical trials.

Augustine EF, Dorsey ER, Hauser RA, Elm JJ, Tilley BC, Kieburtz KK.

Clin Trials. 2016 Dec;13(6):592-596. Epub 2016 Aug 29.

PMID:
27573636
18.

Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial.

Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, Ostwaldt AC, Del Zoppo GJ, Simard JM, Jacobson S, Kimberly WT.

Lancet Neurol. 2016 Oct;15(11):1160-9. doi: 10.1016/S1474-4422(16)30196-X. Epub 2016 Aug 23.

PMID:
27567243
19.

Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.

Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A; MODERATO Investigators.

Mov Disord. 2016 May;31(5):709-14. doi: 10.1002/mds.26617. Epub 2016 Mar 31.

PMID:
27030249
20.

Pilot study of atomoxetine in patients with Parkinson's disease and dopa-unresponsive Freezing of Gait.

Revuelta GJ, Embry A, Elm JJ, Gregory C, Delambo A, Kautz S, Hinson VK.

Transl Neurodegener. 2015 Dec 10;4:24. doi: 10.1186/s40035-015-0047-8. eCollection 2015.

21.

Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design.

Sheth KN, Elm JJ, Beslow LA, Sze GK, Kimberly WT.

Neurocrit Care. 2016 Feb;24(1):132-9. doi: 10.1007/s12028-015-0189-7.

PMID:
26268138
22.

Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.

Augustine EF, Pérez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O.

PLoS One. 2015 Jul 14;10(7):e0133002. doi: 10.1371/journal.pone.0133002. eCollection 2015.

23.

Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale.

Chaisinanunkul N, Adeoye O, Lewis RJ, Grotta JC, Broderick J, Jovin TG, Nogueira RG, Elm JJ, Graves T, Berry S, Lees KR, Barreto AD, Saver JL; DAWN Trial and MOST Trial Steering Committees; Additional contributors from DAWN Trial Steering Committee.

Stroke. 2015 Aug;46(8):2238-43. doi: 10.1161/STROKEAHA.114.008547. Epub 2015 Jul 2.

24.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM.

JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.

25.

Screen failure data in clinical trials: Are screening logs worth it?

Elm JJ, Palesch Y, Easton JD, Lindblad A, Barsan W, Silbergleit R, Conwit R, Dillon C, Farrant M, Battenhouse H, Perlmutter A, Johnston SC.

Clin Trials. 2014 Aug;11(4):467-472. Epub 2014 Jun 12.

26.

Exploratory analysis of glyburide as a novel therapy for preventing brain swelling.

Sheth KN, Kimberly WT, Elm JJ, Kent TA, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, del Zoppo G, Simard JM, Stern BJ, Mandava P.

Neurocrit Care. 2014 Aug;21(1):43-51. doi: 10.1007/s12028-014-9970-2.

27.

Pilot study of intravenous glyburide in patients with a large ischemic stroke.

Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, Simard JM, Stern BJ.

Stroke. 2014 Jan;45(1):281-3. doi: 10.1161/STROKEAHA.113.003352. Epub 2013 Nov 5.

28.

Glyburide is associated with attenuated vasogenic edema in stroke patients.

Kimberly WT, Battey TW, Pham L, Wu O, Yoo AJ, Furie KL, Singhal AB, Elm JJ, Stern BJ, Sheth KN.

Neurocrit Care. 2014 Apr;20(2):193-201. doi: 10.1007/s12028-013-9917-z.

29.

Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.

Connor JT, Elm JJ, Broglio KR; ESETT and ADAPT-IT Investigators.

J Clin Epidemiol. 2013 Aug;66(8 Suppl):S130-7. doi: 10.1016/j.jclinepi.2013.02.015.

30.

Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial.

Luo S, Lawson AB, He B, Elm JJ, Tilley BC.

Stat Methods Med Res. 2016 Apr;25(2):821-37. doi: 10.1177/0962280212469358. Epub 2012 Dec 12.

32.

Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial.

Elm JJ, Palesch YY, Koch GG, Hinson V, Ravina B, Zhao W.

J Biopharm Stat. 2012;22(4):758-72. doi: 10.1080/10543406.2010.528103.

33.

Fall frequency and risk assessment in early Parkinson's disease.

Voss TS, Elm JJ, Wielinski CL, Aminoff MJ, Bandyopadhyay D, Chou KL, Sudarsky LR, Tilley BC; Falls Writing Group NINDS NET-PD Investigators.

Parkinsonism Relat Disord. 2012 Aug;18(7):837-41. doi: 10.1016/j.parkreldis.2012.04.004. Epub 2012 Apr 26.

34.

A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy.

Tilley BC, Mainous AG 3rd, Elm JJ, Pickelsimer E, Soderstrom LH, Ford ME, Diaz VA, Siminoff LA, Burau K, Smith DW.

Clin Trials. 2012 Apr;9(2):188-97. doi: 10.1177/1740774512436881.

35.

Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke.

Yoo AJ, Sheth KN, Kimberly WT, Chaudhry ZA, Elm JJ, Jacobson S, Davis SM, Donnan GA, Albers GW, Stern BJ, González RG.

J Stroke Cerebrovasc Dis. 2013 Aug;22(6):742-9. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.002. Epub 2012 Feb 9.

36.

Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Schneider JS, Elm JJ, Parashos SA, Ravina BM, Galpern WR; NET-PD Investigators.

Parkinsonism Relat Disord. 2010 Sep;16(8):507-12. doi: 10.1016/j.parkreldis.2010.06.001. Epub 2010 Jul 2.

37.

How common is brain atrophy in patients with medial temporal lobe epilepsy?

Bonilha L, Elm JJ, Edwards JC, Morgan PS, Hicks C, Lozar C, Rumboldt Z, Roberts DR, Rorden C, Eckert MA.

Epilepsia. 2010 Sep;51(9):1774-9. doi: 10.1111/j.1528-1167.2010.02576.x.

38.

Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience.

Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S; NINDS NET-PD Investigators and Coordinators.

Mov Disord. 2007 Apr 30;22(6):822-7.

PMID:
17357141
39.

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.

Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC; NET-PD Investigators.

Neurology. 2006 Mar 14;66(5):628-33. Review.

PMID:
16534099
40.

Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.

Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC.

Clin Trials. 2005;2(6):509-18.

PMID:
16422311
41.

A responsive outcome for Parkinson's disease neuroprotection futility studies.

Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators.

Ann Neurol. 2005 Feb;57(2):197-203.

PMID:
15668964

Supplemental Content

Support Center